Skip to main content

Jupiter Neurosciences Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.

Current Price

$0.24

+16.93%
Profile
Valuation (TTM)
Market Cap$7.06M
P/E-0.77
EV
P/B
Shares Out29.44M
P/Sales174.48
Revenue$40448.00
EV/EBITDA

Jupiter Neurosciences Inc (JUNS) Social Sentiment

JUNS Social Sentiment Analysis

Social media sentiment analysis for Jupiter Neurosciences Inc (JUNS). Track bullish and bearish sentiment, mention volume, and BuzzScore trends from StockTwits and Reddit. Social sentiment provides a crowd-sourced view of investor confidence in JUNS.

Current stock price: $0.24. Market cap: $7.06M. This page displays sentiment timelines, bullish vs bearish ratios, total mention counts, peak BuzzScore data, and source breakdowns for JUNS. The sentiment data is updated regularly to reflect the latest social media activity.

Social sentiment is one of many signals to consider when evaluating a stock. High bullish sentiment combined with strong fundamentals may reinforce a buy thesis. Use GoodMoat's sentiment tracking alongside quality analysis, financial data, and valuation models to make well-informed investment decisions about Jupiter Neurosciences Inc.